Can I Take Omega-3 (EPA/DHA) with Trazodone?

Why This Combination Raises Questions

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) prescribed primarily for major depressive disorder and, off-label, for insomnia at lower doses. Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are taken for cardiovascular protection, mood support, and triglyceride reduction. Both are common. Trazodone ranked among the 25 most dispensed medications in the United States in 2023, with over 30 million prescriptions filled according to ClinCalc drug usage statistics. Omega-3 supplements are used by roughly 7.8% of U.S. Adults based on the 2017 National Health Interview Survey published by the National Center for Health Statistics.

Where the Concern Originates

The concern is not about one drug changing the blood level of the other. It is about both agents independently affecting platelet aggregation. When two substances share a pharmacodynamic endpoint (in this case, reduced clot formation), combining them can push bleeding risk higher than either would alone. This is a class-level interaction seen with all serotonin reuptake-affecting antidepressants and any supplement or drug with antiplatelet properties [1].

Who Needs to Pay Attention

For a healthy adult taking trazodone 50 to 150 mg at bedtime for sleep and a standard fish oil capsule providing 500 to 1,000 mg EPA+DHA daily, the absolute risk increase is small. The patients who need to pay close attention are those on triple therapy: trazodone plus omega-3 plus an anticoagulant or antiplatelet drug like warfarin, clopidogrel, or daily aspirin.

The Pharmacodynamic Interaction Explained

This is a pharmacodynamic interaction, not a pharmacokinetic one. Trazodone does not alter EPA or DHA absorption, distribution, or metabolism. Omega-3 fatty acids do not inhibit or induce CYP3A4 or CYP2D6, the two main enzymes responsible for trazodone clearance [2]. Blood levels of trazodone remain unchanged when fish oil is added.

How Trazodone Affects Platelets

Trazodone inhibits the serotonin transporter (SERT) on platelet membranes. Platelets do not synthesize their own serotonin. They rely on uptake from plasma via SERT to fill their dense granules. When SERT is blocked, dense granule serotonin stores deplete over time, and the platelet aggregation response weakens [3]. A 2012 BMJ meta-analysis of 42 observational studies (N = 1,073,652) found that serotonergic antidepressants as a class increased the risk of upper GI bleeding by approximately 55% (adjusted OR 1.55, 95% CI 1.35 to 1.78) compared to non-use [4].

How Omega-3 Fatty Acids Affect Platelets

EPA competes with arachidonic acid for cyclooxygenase (COX) binding sites. The result is a shift from thromboxane A2 (a potent platelet aggregator) toward thromboxane A3, which has much weaker aggregation activity [5]. DHA incorporates into platelet phospholipid membranes and further reduces aggregation sensitivity. A 2013 systematic review published in the American Journal of Clinical Nutrition found that fish oil at doses of 1.8 g/day EPA+DHA and above measurably prolonged bleeding time, though clinically significant hemorrhage was rare [6].

The Additive Effect

Neither agent alone produces a large hemostatic deficit in most people. Together, the concern is additive: trazodone depletes intraplatelet serotonin while EPA/DHA blunt the thromboxane-dependent aggregation pathway. The two mechanisms are independent, which means the combined effect is not synergistic but simply the sum of two modest antiplatelet forces.

Risk Stratification: Who Is Low, Moderate, or High Risk

Not every patient carrying a trazodone prescription and a bottle of fish oil faces the same level of concern. Risk depends on dose, comedications, and individual bleeding history.

Low-Risk Profile

A patient taking trazodone 25 to 100 mg for sleep, omega-3 at 1 g/day or less EPA+DHA, no anticoagulants, no history of GI ulcers or bleeding disorders. This describes the majority of people asking this question. No specific monitoring beyond routine awareness is needed.

Moderate-Risk Profile

A patient taking trazodone at antidepressant doses (150 to 300 mg/day), omega-3 at 2 to 4 g/day EPA+DHA (prescription-strength for triglyceride lowering), or concurrent daily low-dose aspirin (81 mg). These patients should discuss the combination with their prescriber and report any new or increased bruising.

High-Risk Profile

A patient on trazodone at any dose plus omega-3 at any dose who also takes warfarin, apixaban, rivaroxaban, clopidogrel, or prasugrel. Patients with a history of hemorrhagic stroke, active peptic ulcer disease, or thrombocytopenia also fall here. The 2023 American College of Cardiology expert consensus document on managing bleeding risk with antithrombotic therapy recommends minimizing concomitant agents that impair hemostasis in these individuals [7].

What the Evidence Shows About Bleeding Events

Direct randomized trial data on the specific pair of trazodone plus omega-3 do not exist. The evidence base is indirect, built from class-level data on serotonergic antidepressants and fish oil separately.

Serotonergic Antidepressant Bleeding Data

The 2012 BMJ meta-analysis by Anglin et al. (42 studies, N > 1 million) established the 55% relative increase in GI bleeding for serotonergic antidepressants [4]. A 2019 JAMA Internal Medicine cohort study (N = 3,276,854 antidepressant initiators) found that the absolute risk of GI bleeding was 1.6 additional events per 1,000 person-years with SSRIs/SNRIs compared to non-use [8]. Trazodone has weaker serotonin reuptake inhibition than fluoxetine or sertraline, so its individual bleeding contribution is likely at the lower end of the class range.

Omega-3 Bleeding Data

The REDUCE-IT trial (N = 8,179, icosapent ethyl 4 g/day vs. Placebo) reported a statistically significant increase in adjudicated bleeding events: 2.7% in the icosapent ethyl group vs. 2.1% in placebo (P = 0.06 for serious bleeding, P < 0.001 for any bleeding-related event) [9]. At standard supplement doses (1 g/day EPA+DHA), bleeding events in meta-analyses have not exceeded placebo rates significantly [6].

Putting the Numbers Together

Combining a modest antiplatelet effect from trazodone with a modest antiplatelet effect from standard-dose fish oil produces a theoretical additive risk. No published case series or pharmacovigilance signal specifically flags trazodone-plus-omega-3 as a dangerous pair. The bleeding risk is real but small in absolute terms for low-risk patients.

Dose Timing and Practical Guidance

Because this interaction is pharmacodynamic, separating doses by hours does not reduce risk. The antiplatelet effects of both agents persist for the full duration of their pharmacologic activity, not just during peak blood levels.

Optimal Timing for Absorption

Take omega-3 with a fat-containing meal. A 2019 randomized crossover study showed that EPA/DHA bioavailability increased by approximately 3-fold when taken with a high-fat meal compared to fasting [10]. Trazodone for insomnia is typically taken 30 minutes before bedtime, often with a small snack to reduce orthostatic hypotension. Taking omega-3 at dinner and trazodone at bedtime is a reasonable, practical schedule.

Dose Ceilings to Discuss with a Prescriber

The FDA has set 5 g/day EPA+DHA as the upper limit for prescription omega-3 products [11]. For supplemental use, most clinical guidelines suggest 1 to 2 g/day EPA+DHA for mood support and up to 4 g/day for triglyceride reduction. If the prescriber's goal is to treat hypertriglyceridemia with high-dose EPA/DHA in a patient already on trazodone, a conversation about baseline bleeding risk and comedications is appropriate.

Monitoring Recommendations

Routine lab monitoring specifically for this combination is not standard practice. No guideline recommends checking bleeding time or platelet function tests for patients on trazodone plus omega-3 alone.

Clinical Signs to Watch

Patients should report: easy or new bruising, bleeding gums when brushing teeth, nosebleeds lasting longer than 10 minutes, blood in stool or urine, and prolonged bleeding from minor cuts. These are the same signals clinicians advise for any patient on serotonergic antidepressants [3].

When to Order Labs

If a patient on this combination reports any of the signs above, a reasonable workup includes a complete blood count (CBC) with platelet count and a basic coagulation panel (PT/INR, aPTT). If the patient is on warfarin, more frequent INR checks (every 1 to 2 weeks) are warranted after adding or adjusting omega-3 dose, as EPA/DHA may modestly potentiate warfarin's effect [12].

Perioperative Considerations

Surgeons often ask patients to stop fish oil 7 to 10 days before elective surgery because of the theoretical bleeding risk. A 2017 systematic review in Circulation concluded that this practice is not well supported by evidence at supplement doses and that continuing fish oil perioperatively did not significantly increase surgical bleeding [13]. Trazodone does not typically require perioperative discontinuation for bleeding concerns alone. Patients should still disclose both agents to their surgical team.

Potential Mood Benefits of Combining Omega-3 with Trazodone

Beyond the interaction question, some patients take omega-3 specifically because of evidence supporting EPA's adjunctive role in depression treatment.

EPA for Depression: The Evidence

A 2019 meta-analysis in Translational Psychiatry (26 RCTs, N = 2,160) found that omega-3 formulations with EPA at or above 60% of total EPA+DHA content produced a statistically significant antidepressant effect (SMD = 0.50, 95% CI 0.28 to 0.71) when used alongside standard antidepressant therapy [14]. The International Society for Nutritional Psychiatry Research (ISNPR) 2019 guidelines recommend EPA-predominant formulations at 1 to 2 g/day as adjunctive treatment for major depressive disorder [15].

Clinical Relevance for Trazodone Users

For patients taking trazodone at full antidepressant doses (150 to 300 mg/day) with incomplete response, adding 1 to 2 g/day of an EPA-predominant omega-3 supplement is a reasonable adjunctive strategy with a low side-effect burden. The ISNPR guidelines do not specifically address trazodone, but the recommendation applies to serotonergic antidepressants broadly.

What About Triglyceride Effects?

Trazodone has a mildly favorable or neutral effect on lipid profiles. It does not raise triglycerides. Omega-3 at prescription doses (icosapent ethyl 4 g/day or omega-3 acid ethyl esters 4 g/day) reduces triglycerides by 20% to 45% depending on baseline levels [9]. There is no pharmacologic conflict between these agents on lipid metabolism. They can be combined for a patient who needs both mood/sleep support and triglyceride management without concern about opposing metabolic effects.

Special Populations

Older Adults

Patients aged 65 and older are more likely to be on both trazodone (commonly used for insomnia in geriatric populations) and omega-3 (commonly taken for cardiovascular health). They are also more likely to be on anticoagulants or antiplatelet agents. The Beers Criteria list trazodone as potentially inappropriate in older adults with certain fall risk factors, partly because of orthostatic hypotension. Bleeding risk from the trazodone-omega-3 combination adds another consideration. A 2018 JAMA Network Open study showed that adults over 75 on serotonergic antidepressants had an absolute GI bleed rate of approximately 4.2 per 1,000 person-years, roughly double that of younger adults [8].

Pregnancy and Lactation

Trazodone is FDA pregnancy category C (no adequate human studies). Omega-3 supplementation during pregnancy is considered safe and is recommended by ACOG for fetal neurodevelopment [16]. The combination has not been specifically studied in pregnant populations. Pregnant patients should discuss trazodone continuation with their obstetrician, and the omega-3 component does not alter that risk-benefit analysis.

Patients with Liver Disease

Trazodone is extensively hepatically metabolized. Omega-3 fatty acids do not impair hepatic CYP activity. Patients with cirrhosis or significant hepatic impairment may already have coagulopathy due to reduced clotting factor synthesis, which makes any additive antiplatelet effect more clinically relevant. Dose adjustment of trazodone (not omega-3) may be necessary in moderate to severe hepatic impairment [2].

When to Contact Your Prescriber

Contact your prescriber before combining these agents if you: take warfarin, apixaban, rivaroxaban, or any other blood thinner; take daily aspirin or clopidogrel; have a history of GI bleeding, hemorrhagic stroke, or a bleeding disorder; plan to take EPA+DHA at doses above 3 g/day; or are scheduled for surgery within the next two weeks.

For patients already taking both without problems, no change is needed. The combination is well tolerated at standard doses in the absence of additional bleeding risk factors.